BioWorld MedTech

April 26, 2011

Boston Sci receives approval for ION DES

Boston Scientific (BSX; Natick, Massachusetts) reported approval and launch of the Ion paclitaxel-eluting platinum chromium coronary stent system, the company's third-generation drug-eluting stent (DES) technology. (Medical Device Daily) Read More

Gore reports the enrollment of first TIPS study patient

International report: CryoLife to distribute BioGlue in Japan

Washington roundup: Updated human factors guidance requires further clinical data

Agreements/contracts: Philips, NEC combine their digital pathology solutions

Coming Wednesday in MDD Perspectives: Industry and public can help provide safeguards against unethical research

Court Report: Jury awards St. Jude $2.3B in trade secret violations case

Financings roundup: Oxford Finance gets new $460M capital infusion

Deals roundup: Tenet board again rejects acquisition offer from CHS

Product Briefs

People in the News

MDD's Cardio Extra

Today's news in brief

BioWorld

BioWorld briefs for April 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 14, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...

ADPD 2025: Novel treatment modalities in neurodegenerative disorders

BioWorld Science

The current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease...